Divestment gains push Orchid back to net profit
This article was originally published in Scrip
Orchid Chemicals and Pharmaceuticals has reported a consolidated net profit of Rs3.39 billion ($72 million) for the year ended 31 March 2010, as against a net loss of Rs490 million in the previous fiscal year. The move back into the black was largely on account of gains from the sale of its generic injectables finished dosage business to Hospira.
You may also be interested in...
Plus deals involving LegoChem/Pyxix, Biohaven/Sosei Heptares, Kyowa Kirin/Helsinn, Dr. Reddy’s/Glenmark, Eisai/Wren, KoBioLabs/Kolmar Korea, Y-Biologics/Pierre Fabre, Generex/Chinese consortium.
A senior executive shares insights around how the global logistics provider is preparing to deliver the upcoming COVID-19 vaccines across the world. While the company has prior experience with the "deep frozen" temperatures needed for some candidates, there will still be specific challenges and complexities involved.
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.